Source: Kidneys; a drawing by Europeana on Unsplash

In the final part of our mini-series from ASCO GU on strategic analyses, we move on to renal cell carcinoma (RCC), where a critical look at the data reveals several new potential high impact areas, as well as novel targets to watch out for.

These may be reshaping the evolving treatment landscape in a quiet way.

It won’t be all rose tinted glasses though because while RCC is moving into their next chapter, the hard questions are just starting to emerge…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers